Navigation Links
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
Date:11/13/2013

DEERFIELD, Ill., Nov. 13, 2013 /PRNewswire/ -- Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile.

BAX 855 was designed based on the full-length ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] molecule, a product with 10 years of real-world experience. The BAX 855 molecule was modified with PEGylation technology designed to extend its duration of activity in the body.

"The BAX 855 development program is a priority for Baxter as we evaluate the potential to provide an efficacious and safe treatment with an extended half-life for patients with hemophilia," said Anders Ullman, M.D., Ph.D., vice president of global research and development in Baxter's BioScience business. "We are focused first and foremost on strategies to address optimal efficacy and minimize patients' bleeding episodes, while at the same time delivering on the convenience of less frequent dosing for this population with severe disease."

The Phase II/III multi-center, open-label study called PROLONG-ATE is evaluating BAX 855 among 146 adult patients with previously-treated severe hemophilia A. Patients participating in PROLONG-ATE receive treatment twice weekly (45 IU/kg) and are followed for six months. The primary endpoint of the study is the annualized bleed rate (ABR) during the treatment period.  The study is also evaluating the safety and immunogenicity of the compound when administered on either prophylaxis and on-demand treatment regimens. Other outcome measures include number of infusions needed t
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology news :

1. NSF report detailing growth in graduate enrollment in science & engineering in the past decade
2. King Richard III search in new phase after discovery has potential to rewrite history
3. National Geographic unveils new phase of genographic project
4. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
5. In beef production, cow-calf phase contributes most greenhouse gases
6. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
7. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
8. Carnegie Mellon neuroscientists discover new phase of synaptic development
9. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
10. New sickle cell anemia therapy advances to Phase II clinical trials
11. Biozoom Enters Into Commercial Phase of Scanner Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... which could harm the birds fitness and ability to ... Ecological Societys Journal of Applied Ecology, researchers warn that ... they are inhabited by capercaillie - a species whose ... study by ecologists from Switzerland, Germany and Austria used ...
... imaging of impact strata on Mars, Holden Crater; ... evidence that liquid water is not responsible for ... into Cretaceous early Albian greenhouse conditions and implications ... of Earth,s copper supply; discovery of large nitrate ...
... genetic study has revealed why chickens have yellow legs, ... things, his view on the origins of the chicken ... 29 in the open-access journal PLoS Genetics, reveals the ... billions of chickens raised worldwide. Yellow-skinned chickens ...
Cached Biology News:March GEOLOGY and GSA TODAY media highlights 2March GEOLOGY and GSA TODAY media highlights 3March GEOLOGY and GSA TODAY media highlights 4March GEOLOGY and GSA TODAY media highlights 5March GEOLOGY and GSA TODAY media highlights 6March GEOLOGY and GSA TODAY media highlights 7March GEOLOGY and GSA TODAY media highlights 8March GEOLOGY and GSA TODAY media highlights 9March GEOLOGY and GSA TODAY media highlights 10March GEOLOGY and GSA TODAY media highlights 11March GEOLOGY and GSA TODAY media highlights 12March GEOLOGY and GSA TODAY media highlights 13March GEOLOGY and GSA TODAY media highlights 14March GEOLOGY and GSA TODAY media highlights 15Study shows Darwin was wrong about the origins of chickens 2
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... San Diego , CA (PRWEB) , ... July ... ... Biopharma, announced the successful completion of a field clinical study of its canine ... being developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
(Date:7/29/2015)... , July 30, 2015 ... la santé, publie ses résultats pour le premier ... commente les résultats. Visionner l,interview ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de ... - Moteurs de croissance - ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... about the emergence of some new angel groups in Illinois as ... funds focused on early stage funding. I have been struck by ... for this as most of the Midwests biotech companies are early ... has also been a dearth of funding for this type of ...
... its Imaging and Printing Group and its Personal Systems Group ... major milestone in HPs journey to become the ... has a unified and convincing product message for every room ... turns HPs consumer message into overdrive. , ,The consumer technology ...
... (2004, Harvard Business School Press) takes a detailed look at ... playing them. , ,Authors John C. Beck and ... give business managers a lesson on how to handle the ... thinking on competitiveness, risk-taking and everything else are ...
Cached Biology Technology:Midwest angel investment in life sciences on the rise 2Midwest angel investment in life sciences on the rise 3Midwest angel investment in life sciences on the rise 4Midwest angel investment in life sciences on the rise 5Midwest angel investment in life sciences on the rise 6HP charges toward the living room 2HP charges toward the living room 3Got Game makes big claims; can 90 million people think the same? 2
... uses three Adept CE 4100 high pressure ... rate in one microlitre increaments. The ... provides added flexibility. The WaveQuest ... array detection and provides superior stability . ...
... of samples may be carried out using this ... System control and data processing is provided ... The elegant, powerful and very easy to use ... and 2000., The supplied detector is the ground ...
...
capacity 250 mL...
Biology Products: